Chronic hepatitis C responds poorly to combination therapy in chronic hepatitis B carriers

Netherlands Journal of Medicine

Volumn 66, Issue 5, 2008, Pages 191-195

  Senturk, H ^a   Tahan, V ^b   Canbakan, B ^a   Uraz, S ^c   Ulger, Y ^a   Ozaras, R ^a   Tabak, F ^a   Mert, A ^a   Ozbay, G ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

Author keywords

Chronic hepatitis B; Chronic hepatitis C; Co infection; Dual infection; Pegylated interferon

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; MALE; NAUSEA; PATIENT COMPLIANCE; PNEUMONIA; POLYMERASE CHAIN REACTION; PRURITUS; SIDE EFFECT; SUPERINFECTION; THROMBOCYTOPENIA; VIRUS DETECTION; WEAKNESS;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 44649150222     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lee W. Hepatitis B virus infection N Engl J Med 1997;337:1733-45.
2. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Hepatology 2002:36(Suppl 1):3-20.
3. Stroffolini T, Sagnelli E, Mele A, Craxi A, Almasio P and Italian Hospitals Collaborating Group. The etiology of Chronic Hepatitis in Italy: Results from a multicentre national study. Dig Liver Dis 2004;36:829-33.
4. Zarski J-P, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33.
5. Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001;34:404-10.
6. Mathurin P, Thibault V, Kadidja, et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepatitis 2000;7:15-22.
7. Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003:39:1036-41.
8. Sagnelli E, Pasquale G, Coppola N, et al. Influence of chronic infection with hepatitis B and C virus on liver histology. Infection 2004;32:144-8.
9. Villa E, Grottola A, Buttafaco P, et al. High doses of alfa-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: Long term results of a prospective randomized trial. Am J Gastroenterol 2001;96:2973-7.
10. Fukuda R, Ishimura N, Nigaki M, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus associated chronic liver disease: Clinical and virological significance. J Med Virol 1999;58:201-7.
11. Lee DS, Huh K, Lee EH, Lee DH, Hong KS, Sung YC. HCV and HBV coexist in HBsAg-negative patients with HCV viraemia: Possibility of coinfection in these patients must be considered in HBV-high endemic area. J Gastroenterol Hepatol 1997;12:855-61.
12. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, Piccinino F. HCV genotype and silent HBV coinfection: Two main risk factors for a more severe liver disease. J Med Virol 2001;64:350-5.
13. Kubo S, Nishiguchi S, Hirohashi K, et al. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999;86:793-8
14. Ruiz J, Sangro B, Cuende JI, et al. Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology 1992;16:637-41.
15. Shiratori Y, Shiina S, Zhang PY, et al. Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan. Cancer 1997;80:2060-7.
16. Zignego AL, Fontana R, Puliti S, et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997;51:313-8.
17. Weltman MD, Brotodihardjo A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995;2:39-45.
18. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003;37:568-76.
19. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
20. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
21. Rautou PE, Asselah T, Saadoun D, Martinot M, Valla D, Marcellin P. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-a2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. Eur J Gastroenterol Hepatol 2006,18:1019-22.
22. Chomcynski P, Sacci N. Single step method of RNA isolation by acid-guanidium thiocyanate-phenol-chloroform axtraction. Anal Biochem 1984;162:156-9.
23. Shih CM, Lo SJ, Miyamura T, Chen SY, Lee YH. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993;67:5823-32.
24. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, Changchien CS. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005;20:727-32.
25. Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004;20:825-30.
26. Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800.
27. Liaw YF, Chien RN, Lin SM, et al. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997;17:449-52.
28. Utili R, Zampino R, Bellopede P, et al. Dual or single hepatitis B and C virus infections in childhood cancer survivors: long-term follow-up and effect of interferon treatment. Blood 1999,94:4046-52.
29. Guptan RC, Thakur V, Raina V, Sarin SK. Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses. J Gastroenterol Hepatol 1999;14:893-8.
30. Marrone A, Zampino R, D'Onofrio M, Ricciotti R, Ruggiero G, Utili R. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 2004;41:1064-5.
31. Chuang WL, Dai CY, Chang WY, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005;10:125-33.